Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 6Completed 5Withdrawn 3Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 10Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Neoplasm Metastasis 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1SCLC,Extensive Stage 1Rare Tumor 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Adenocarcinoma Metastatic 1Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Laryngeal Diseases 1Hemangiosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

Fulvestrant 60Capecitabine 47Trastuzumab 46Letrozole 45pembrolizumab 42Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37abemaciclib 36pertuzumab 34Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Surveys and Questionnaires 26Docetaxel 26Tamoxifen 25Anastrozole 25exemestane 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × niraparib × Clear all
NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Recruiting
484 enrolled
Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GlaxoSmithKline

Phase 2 Recruiting
30 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡